Tema GLP-1, Obesity & Cardiometabolic ETF (NQ: HRTS )

34.15 -1.13 (-3.20%)

Official Closing Price Updated: 4:15 PM EDT, Jul 18, 2024 Add to My Watchlist

Price and Volume

Volume	29,020
Open	35.16
Bid (Size)	34.08 (7)
Ask (Size)	34.15 (1)
Prev. Close	35.28
Today's Range	34.00 - 35.20
52wk Range	26.26 - 36.03
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO

July 07, 2024

The GLP-1 drug market for obesity treatment is expected to skyrocket to $1 trillion or more, according to Maurits Pot, founder and CEO of Tema ETFs.

Via Benzinga

What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients

July 05, 2024

A number of companies are working on new drugs for high lipids, including cholesterol and triglycerides.

Via Investor's Business Daily

Performance

YTD	+11.40%	+11.40%
1 Month	+5.04%	+5.04%
3 Month	+9.39%	+9.39%
6 Month	+10.23%	+10.23%
1 Year	+28.26%	+28.26%

More News

Weight-Loss Drug Forecasts Skyrocket To $150B As Novo Nordisk, Eli Lilly Ramp Up Supply

May 29, 2024

Via Benzinga

Eli Lilly Pops After Weight-Loss Drug Succeeds In Highly Anticipated Sleep Apnea Test

April 17, 2024

Via Investor's Business Daily

Healthcare ETFs For The Weight-Loss Drug Boom And Beyond

April 08, 2024

Via Talk Markets

Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On.

February 23, 2024

Via Investor's Business Daily

Ozempic, Weygovy – Obesity And Heart Health Constitute A Major Market That Is Only Growing

January 29, 2024

Via Benzinga

Roche, Pfizer Race To Find Next Ozempic As Pharma Giants Hustle To Join Obesity Treatment Market

December 04, 2023

Via Benzinga

EXCLUSIVE: Tema ETFs' Innovative Thematic Investing Approach Targets New Opportunities Beyond The Fads

December 01, 2023

Via Benzinga

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.